Drug intelligence / Profile preview

ITBSC-32

Development stage: Preclinical
Lead developer: BiSiChem
Modality: Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems

Overview

ITBSC-32 is a preclinical-stage therapeutic candidate developed by BiSiChem that utilizes lipid nanoparticle (LNP) technology to target the Stimulator of Interferon Genes (STING) pathway. By activating STING, the drug aims to stimulate the innate immune system to produce Type I interferons and pro-inflammatory cytokines, thereby promoting a robust anti-tumor immune response. This approach is typically explored in the context of immuno-oncology to turn "cold" tumors "hot" and enhance the efficacy of other immunotherapies.

Targets

STING (Stimulator of interferon genes protein)

Beyond the preview

Go deeper on ITBSC-32.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ITBSC-32.

Explore the full profile